News
ACXP
1.040
-1.89%
-0.020
Weekly Report: what happened at ACXP last week (1102-1106)?
Weekly Report · 1d ago
Fusion Power, Global Capital, Branded Streaming and Neurology Breakthroughs: New to The Street Show #779 Premieres Tonight on Bloomberg Television
Barchart · 3d ago
Acurx Pharmaceuticals, Inc. Amends Bylaws to Reduce Stockholder Quorum to 33⅓%
NASDAQ · 11/03 02:18
Weekly Report: what happened at ACXP last week (1026-1030)?
Weekly Report · 11/02 10:17
From Global Private Credit to Programmable Securities: New to The Street Show #778 Premieres Tonight on Bloomberg Television
Barchart · 10/31 10:00
Acurx Pharmaceuticals Lowers Quorum for Shareholder Meetings
TipRanks · 10/29 21:49
Press Release: Acurx Pharmaceuticals to Discuss Third Quarter 2026 Financial Results on November 12, 2026 Conference Call and Provide Business Update
Dow Jones · 10/26 12:01
Weekly Report: what happened at ACXP last week (1019-1023)?
Weekly Report · 10/26 10:17
From Private Credit to Fusion Power: New to The Street Show #777 Premieres Tonight on Bloomberg Television
Barchart · 10/24 09:30
12 Health Care Stocks Moving In Thursday's Pre-Market Session
Benzinga · 10/22 12:05
Acurx Announces Publication in ASM Confirming Data on its DNA pol IIIC Inhibitor Pipeline of Antibiotics Demonstrating a Potential Microbiome-Sparing Class Effect
PR Newswire · 10/21 12:01
Weekly Report: what happened at ACXP last week (1012-1016)?
Weekly Report · 10/19 10:17
Acurx Pharmaceuticals Shareholders Approve Governance and Auditing Changes
TipRanks · 10/16 21:00
Weekly Report: what happened at ACXP last week (1005-1009)?
Weekly Report · 10/12 10:22
Acurx Pharmaceuticals Takes Its Antibiotics Story Global Through a 12-Month Series with New to The Street
Barchart · 10/05 12:25
Weekly Report: what happened at ACXP last week (0928-1002)?
Weekly Report · 10/05 10:22
Analysts Are Bullish on Top Healthcare Stocks: Abbott Laboratories (ABT), Tectonic Therapeutic (TECX)
TipRanks · 09/30 08:50
Advancing C. Difficile Program Supports Unchanged $31 Price Target and Buy Rating
TipRanks · 09/29 15:55
Acurx Pharmaceuticals Price Target Maintained With a $31.00/Share by HC Wainwright & Co.
Dow Jones · 09/29 15:53
HC Wainwright & Co. Reiterates Buy on Acurx Pharmaceuticals, Maintains $31 Price Target
Benzinga · 09/29 15:43
More
Webull provides a variety of real-time ACXP stock news. You can receive the latest news about Acurx Pharmaceuticals Inc through multiple platforms. This information may help you make smarter investment decisions.
About ACXP
Acurx Pharmaceuticals, Inc. is a late-stage biopharmaceutical company focused on developing a new class of small molecule antibiotics for difficult-to-treat bacterial infections. It develops antibiotic candidates with a Gram-positive selective spectrum (GPSS) that block the active site of the Gram positive specific bacterial enzyme deoxyribonucleic acid (DNA) polymerase IIIC (pol IIIC), inhibiting DNA replication and leading to Gram-positive bacterial cell death. Its research and development (R&D) pipeline include antibiotic product candidates that target Gram-positive bacteria, including Clostridioides difficile (C. difficile), methicillin-resistant Staphylococcus aureus (MRSA), vancomycin resistant Enterococcus (VRE), drug-resistant Streptococcus pneumoniae (DRSP) and B. anthracis (anthrax; a Bioterrorism Category A Threat-Level pathogen). Its lead antibiotic candidate, ibezapolstat targets the pol IIIC enzyme.